JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus  Joerg Wenzel, Nadine van Holt, Judith Maier, Maria Vonnahme, Thomas Bieber, Dominik Wolf  Journal of Investigative Dermatology  Volume 136, Issue 6, Pages 1281-1283 (June 2016) DOI: 10.1016/j.jid.2016.02.015 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Clinical and histological findings of chilblain lupus erythematosus before and after treatment with ruxolitinib. (a–c) Erythrosquamous plaques at (a) fingers and (b) ear helix, and (c) livid nodules at the tips of the toes of a 69-year-old woman. (d) Histology of lesional biopsy of finger (hematoxylin and eosin stain). Scale bar = 100 μm; original magnification ×20. Interface dermatitis with hydropic degeneration. (e) MxA immunohistology of lesional biopsy of finger (M143-antibody with fast red as chromogen). Scale bar = 100 μm; original magnification ×10. (f, g) Clinical presentation (f) before resumption of ruxolitinib therapy and (g) after 4 months of treatment with ruxolitinib at 2 × 20 mg/d. Journal of Investigative Dermatology 2016 136, 1281-1283DOI: (10.1016/j.jid.2016.02.015) Copyright © 2016 The Authors Terms and Conditions